[ET Net News Agency, 8 October 2018] CSPC Pharmaceutical (01093) said it has entered
into an agreement with Sinocelltech in relation to the licensing and commercialization of
an antiCD20 monoclonal antibody for injection (SCT400) developed by Sinocelltech. The
product is currently undergoing phase III clinical trials in China for the indication of
non-Hodgkin's lymphoma and biologics license application is expected to be filed in the
first quarter of 2019.
The company agrees to pay to Sinocelltech upfront and development milestone payments of
up to a maximum amount of RMB650 million. (SC)